Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD)
frequently occur together and their coexistence is associated with worse outcomes than …

Importance There are 30 million adults (12%) in the United States who have chronic
obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease accounts for …

Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy,
consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 …

Background: North American and European health agencies recently warned of severe
breathing problems associated with gabapentinoids, including in patients with chronic …

Heart failure (HF) and chronic obstructive pulmonary disease (COPD) coincide in a
significant number of patients. Recent population-based registries suggest that spirometry is …

Background Triple therapy combinations of a long-acting muscarinic antagonist (LAMA), a
long-acting beta 2-agonist (LABA), and an inhaled corticosteroid (ICS) for COPD were …

Over the last few years, there has been a renewed interest in patients with characteristics of
both asthma and COPD. Although the precise definition of asthma-COPD overlap (ACO) is …

Recently, two “fixed triple” single-inhaler combinations of an inhaled corticosteroid (ICS), a
long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) have …

Introduction Accumulated high-quality data from randomised controlled trials (RCTs)
indicate that long-acting muscarinic antagonist (LAMA)/long-acting β2 agonist (LABA) …

Obstructive lung diseases, including asthma and COPD, are characterized by air-flow
limitation. Bronchodilator therapy can often decrease symptoms of air-flow obstruction by …